Dottorato in Medicina Molecolare

- Vitale C, Lu X, Abderrahman B, TakahashiK, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol. 2015 Aug 7.

- Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedè P, Riganti C, Palumbo A, Boccadoro M, Massaia M.  Anergic bone marrow Vgamma9Vdelta2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. OncoImmunology. 2015 May 26;4(11):e1047580.

- Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget. 2015 Oct 6;6(30):29833-46.

- Alattar ML*, Ciccone M*, Gaballa MR*, Vitale C*, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 May 26:1-3. [Epub ahead of print] *equally contributing authors

- Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S, Deaglio S. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.  Leukemia. 2015 Feb;29(2):356-68.

- Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment for patients with chronic lymphocytic leukemia.  Leuk Lymphoma. 2015 Jun;56(6):1878-80. 

- Coscia M*, Vitale C*, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood. 2012 Oct 18;120(16):3271-9. *equally contributing authors

- Castella B*, Vitale C*, Coscia M, Massaia M. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci. 2011 Jul;68(14):2419-32. *equally contributing authors

- Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011 May;25(5):828-37.

- Mariani S, Hwang SY, Foglietta M, Bonello L, Vitale C, Coscia M, Fiore F, Bruno B, Massaia M. Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Exp Hematol. 2009 Jun;37(6):728-38.

 

2015:

Ofatumumab and Lenalidomide for Patients with Relapsed CLL: Correlation Between Responses and Immune Characteristics. Vitale C, Falchi L, ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O’Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Final Contest Under40 in Hematology - Giovani Ematologi a confronto. November 12-13, 2015, Villafranca di Verona, Italy.

2014:

The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. Vitale C, Griggio V, Riganti C, Campia I, Robino M, Rigoni M, Sciancalepore P, Foglietta M, Castella B, Boccadoro M, Massaia M, Coscia M. ASH Annual Meeting, San Francisco, December 2014.

Inquadramento diagnostico del paziente nella pratica clinica e Paziente anziano FIT: gestione clinico-terapeutica. Corso “Il paziente con leucemia linfatica cronica: gestione clinica e scelte terapeutiche”, May 30, 2014, Torino, Italy.

 

2015:

Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL treated with Ofatumumab and Lenalidomide. Vitale C, Falchi L, ten Hacken E, Gao H, Shaim H,  Van Roosbroeck K, Calin G, O’Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. ASH Annual Meeting, Orlando, December 2015.

The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Griggio V, Vitale C, Riganti C, Kopecka J, Dal Bo M, Rossi D, Pozzato G, Laurenti L, Zallio F, Marchetti M, Ruggeri M, Omedè P, Del Poeta G, Gattei V, Gaidano G,  Boccadoro M, Massaia M, Coscia M.  ASH Annual Meeting, Orlando, December 2015.

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL). Takahashi K, Vitale C, Bueso-Ramos C, Wang F, Kim E, Zhang J, Gumbs C, Routbort M, Estrov Z, Jain N, Garcia-Manero G, Kantarjian HM, Burger JA,  Ferrajoli A, Keating MJ, Futreal A, Wierda WG. ASH Annual Meeting, Orlando, December 2015.

Front‐line Treatment with Ofatumumab in Elderly Unfit Patients with CLL. Vitale C, Ciccone M, Hinojosa C, Keating MJ, Pemmaraju N, O'Brien S, Wierda WG, Thomas D, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. III annual meeting of the Society of Hematologic Oncology (SOHO), Houston, Texas, 16-19 September 2015.

Other cancers in longterm survivor patients with chronic lymphocytic leukemia. Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom SS, Wierda WG, Ferrajoli A. III annual meeting of the Society of Hematologic Oncology (SOHO), Houston, Texas, 16-19 September 2015.

Ofatumumab as front-line treatment in elderly unfit patients with chronic lymphocytic leukemia. Vitale C, Ciccone M, Hinojosa C, Keating MJ, Pemmaraju N, O'Brien S, Wierda WG, Thomas D, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. XVI International Workshop on Chronic Lymphocytic Leukaemia (IWCLL), Sydney, Australia, 7-9 September 2015.

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom SS, Wierda WG, Ferrajoli A. XVI International Workshop on Chronic Lymphocytic Leukaemia (IWCLL), Sydney, Australia, 7-9 September 2015.

Changes in lymphocyte subsets, angiogenic factors and plasma cytokines in patients with chronic lymphocytic leukemia during treatment with Ofatumumab and Lenalidomide. Vitale C, ten Hacken E, Gao H, Keating MJ, O’Brien S, Wierda WG, Falchi L, Reuben J, Burger JA, Calin G, Ferrajoli A. European Hematology Association (EHA) Annual Meeting, Vienna, Austria, June 2015.

2014:

Bleeding Diathesis Associated with Acquired von Willebrand Syndrome in Three Patients with Chronic Lymphocytic Leukemia. Vitale C, Alattar ML, Ciccone M, Gaballa M, Badoux X, Manoukian G, Keating M, Kroll M, Ferrajoli A.  SOHO Annual Meeting, Houston, September 2014. 

Early results of a phase II study of ofatumumab as front-line treatment in elderly, unfit patients with chroic lymphocytic leukemia (CLL). Ciccone M, Vitale C, Hinojosa C, Keating MJ, Pemmaraju N, O'Brien S, Burger JA, Thomas DA, Kantarjian H, Strati P, Wierda WG, Ferrajoli A. 56th American Society of Hematology Meeting, San Francisco, CA, December 2014.

Identification and functional characterization of antibody responses induced by autoantigens in chronic lymphocytic leukemia. Griggio V, Mandili G, Vitale C, Capello M, Robino M, Rigoni M, Foglietta M, Castella B, Sciancalepore P, Macor P, Novelli F, Boccadoro M, Massaia M, Coscia M. Congress of the Italian Society of Experimental Hematology (SIES), Rimini, Italy, October 2014.

Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma. Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Vitale C, Griggio V, Canepari ME, Robino M, Massaia M. Congress of the Italian Society of Experimental Hematology (SIES), Rimini, Italy, October 2014.

The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells.  Rigoni M, Riganti C, Griggio V, Coscia M, Castella B, Foglietta M, Vitale C, Sciancalepore P, Robino M, Boccadoro M, Massaia M. Congress of the Italian Society of Experimental Hematology (SIES), Rimini, Italy, October 2014.

Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia. Griggio V, Mandili G, Vitale C, Capello M, Robino M, Rigoni M, Foglietta M, Castella B, Sciancalepore P, Canepari ME, Novelli F, Boccadoro M, Massaia M, Coscia M. European Hematology Association (EHA) Annual Meeting, Milano, Italy, June 2014.

 

2015:

- American Society of Hematology (ASH) Annual Meeting. Orlando, 5-8 December 2015

- Final Contest Under40 in Hematology - Giovani Ematologi a confronto.  Villafranca di Verona, Italy, 12-13 November, 2015,

- GIMEMA Working Party Malattie Linfoproliferative Croniche. Roma, Italy, 13 October 2015.

- Hematology Experience Exchange Meeting. Madrid, Spain, 8-9 October, 2015.

- European Hematology Association (EHA) Annual Meeting, Vienna, Austria, June 2015

- Hematologic Malignancies Demystified. Houston, Texas, February 21, 2015. 

 2014:

- European Hematology Association (EHA) Annual Meeting. Milano, 12-15 June 2014

- Society of Hematologic Oncology (SOHO) Annual Meeting. Houston, 17-20 September 2014

- American Society of Hematology (ASH) Annual Meeting. San Francisco, 5-9 December 2014

 

2015:

- Graduate Medical Education (GME) Core Curriculum Lecture Series. August 2014 - August 2015.  Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.

- Graduate Medical Education (GME) Competency Lecture Series. August 2014 - August 2015.  Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.

- 2014-2015 Weekly Hematology Lectures. Leukemia Fellowship Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 

 2014:

- Leucemia mieloide acuta: strategie terapeutiche nel paziente anziano. Prof. Sergio Amadori. Torino, 18 March 2014

- Anemie emolitiche non congenite. Prof. Francesco Rodeghiero. Torino, 15 April 2014

- Piastrinopenie. Prof. Alberto Zanella. Torino, 13 May 2014 2014

 2013:

- Corso teorico-pratico di metodologia e conduzione degli studi clinici in ematologia. Milano, 17-18 January 2013.

 - La statistica negli studi sperimentali. Roma, 19 April 2013.

 - Corso di Biostatistica. Scuola di Dottorato di Scienze della Vita e della Salute. Torino, 13/18/20 June 2013.

 - Seminari di Ematologia: novità diagnostico terapeutiche – Leucemia linfoblastica acuta: MRD e nuovi farmaci. Prof. Renato Bassan. Torino, 26 November 2013.

 

- August-September 2013: Observer. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

- August 2014-August 2015: Clinical Fellow. Leukemia Fellowship Program. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas